Company intelligence / Profile preview

Spectral Medical Inc.

Toronto, Ontario, Canadax.com ↗

Ownership: Public · EDT
Employees: ~29
Development stage: Phase 3

Overview

Completed enrollment of 157 patients in the Tigris Trial with topline results expected in August 2025. The company is seeking U.S. FDA approval for its PMX device.

Therapeutic areas: Infectious Diseases
Modalities: Medical device (hemoperfusion device)Diagnostic assay
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

PMX (Toraymyxin)

Phase 3

Indications: Endotoxic septic shock

1 more asset in the full pipeline.

Request access →

Partnerships

Vantive US Healthcare LLC

Beyond the preview

Go deeper on Spectral Medical Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spectral Medical Inc..

Explore the full profile